Entera Bio Ltd. is a biotechnology startup with a focus on developing innovative oral delivery of therapeutic proteins. Founded in 2010, the company is currently conducting clinical trials on its proprietary technology that enables oral delivery of large molecules and biologics while enhancing their absorption in the GI tract. This addresses the challenges of oral drug delivery for large molecule APIs, including poor absorption and rapid degradation by enzymes and acids in the gastrointestinal tract.
Entera Bio's last investment of $6.60MPost-IPO Equity investment was made on 26 December 2023. The investment was aimed at further advancing their pioneering oral delivery technology. With a focus on biopharma, biotechnology, and pharmaceutical industries, Entera Bio is positioned to bring disruptive solutions to the healthcare sector.
VarmX
